Clarifying the diffuse gliomas: an update on the morphologic features and markers that discriminate oligodendroglioma from astrocytoma.

Diffuse gliomas are the most common brain tumors and include astrocytomas, oligodendrogliomas, and oligoastrocytomas. Their correct pathologic diagnosis requires the ability to distinguish astrocytic from oligodendroglial differentiation in histologic sections, a challenging feat even for the most experienced neuropathologist. Interobserver variability in the diagnosis of diffuse gliomas has been high owing to subjective diagnostic criteria, overlapping morphologic features, and variations in training and practice among pathologists. A select, albeit imperfect, group of molecular and immunohistochemical tests are available to assist in diagnosis of these lesions. Combined loss of chromosomes 1p and 19q is a genetic signature of oligodendrogliomas, whereas gains of chromosome 7 in the setting of intact 1p/19q are more typical of astrocytomas. Detection of amplified epidermal growth factor receptor favors the diagnosis of high-grade astrocytomas over anaplastic oligodendroglioma, which is especially relevant for small cell astrocytomas. Strong nuclear staining for p53 often reflects TP53 mutation and is typical of low-grade astrocytomas. The Olig family of transcription factors has not demonstrated their diagnostic usefulness. Diffuse gliomas remain a diagnostic challenge, and new markers are needed for proper classification and directed therapies.

[1]  P. Bailey,et al.  Oligodendrogliomas of the brain , 1929 .

[2]  N. Ringertz Grading of gliomas. , 2009 .

[3]  Kernohan Jw,et al.  Tumors of the central nervous system , 1965 .

[4]  L. J. Rubinstein,et al.  Tumors of the central nervous system , 1972 .

[5]  B. Scheithauer,et al.  Surgical Pathology of the Nervous System and its Coverings , 1976 .

[6]  Frozen section interpretation in surgical neuropathology. II. Intraspinal lesions. , 1977 .

[7]  V. Armbrustmacher,et al.  Grading of oligodendrogliomas , 1983, Cancer.

[8]  Hermona Soreq,et al.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin , 1985, Nature.

[9]  P. Burger Use of cytological preparations in the frozen section diagnosis of central nervous system neoplasia , 1985, The American journal of surgical pathology.

[10]  G. Eide,et al.  Oligodendroglioma. Histologic Evaluation and Prognosis , 1986, Journal of neuropathology and experimental neurology.

[11]  R. McLendon,et al.  Clinicopathologic correlations in the oligodendroglioma , 1987, Cancer.

[12]  J. Rey,et al.  Chromosomal composition of a series of 22 human low-grade gliomas. , 1987, Cancer genetics and cytogenetics.

[13]  L. Lunsford,et al.  Touch preparations in the rapid intraoperative diagnosis of central nervous system lesions. A comparison with frozen sections and paraffin-embedded sections. , 1988, Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc.

[14]  K. M. Sweeney,et al.  CT-assisted stereotactic brain biopsy: value of intraoperative frozen section diagnosis. , 1988, Journal of neurology, neurosurgery, and psychiatry.

[15]  P. Kelly,et al.  Grading of astrocytomas: A simple and reproducible method , 1988, Cancer.

[16]  T. H. van der Kwast,et al.  Prognostic implications of glial fibrillary acidic protein containing cell types in oligodendrogliomas , 1990, Cancer.

[17]  M. Reyes,et al.  Imprints, smears, and frozen sections of brain tumors. , 1991, Neurosurgery.

[18]  C. James,et al.  Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo. , 1991, Cancer research.

[19]  T. H. van der Kwast,et al.  Ultrastructural Characterization of Transitional Cells in Oligodendrogliomas , 1992, Journal of neuropathology and experimental neurology.

[20]  P. Humphrey,et al.  Structural alterations of the epidermal growth factor receptor gene in human gliomas. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[21]  I. Petersen,et al.  Evidence for a tumor suppressor gene on chromosome 19q associated with human astrocytomas, oligodendrogliomas, and mixed gliomas. , 1992, Cancer research.

[22]  J. Rey,et al.  Molecular analysis of chromosomh 1 abnormalities in human gliomas reveals frequent loss of 1p in oligodendroglial tumors , 1994, International journal of cancer.

[23]  G. Reifenberger,et al.  Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. , 1994, The American journal of pathology.

[24]  Mixed oligoastrocytomas: a survival and prognostic factor analysis. , 1994 .

[25]  J. Cairncross,et al.  p53 mutation, expression, and DNA ploidy in evolving gliomas: evidence for two pathways of progression. , 1994, Journal of the National Cancer Institute.

[26]  V. Ganju,et al.  Region‐specific loss of heterozygosity on chromosome 19 is related to the morphologic type of human glioma , 1995, Genes, chromosomes & cancer.

[27]  D. Louis,et al.  Shared Allelic Losses on Chromosomes 1p and 19q Suggest a Common Origin of Oligodendroglioma and Oligoastrocytoma , 1995, Journal of neuropathology and experimental neurology.

[28]  Susan M. Chang,et al.  Necrosis as a prognostic factor in glioblastoma multiforme , 1996, Cancer.

[29]  E G Stopa,et al.  Observer reliability in histological grading of astrocytoma stereotactic biopsies. , 1996, Journal of neurosurgery.

[30]  E. Schröck,et al.  Recurrent gain of chromosome arm 7q in low‐grade astrocytic tumors studied by comparative genomic hybridization , 1996, Genes, chromosomes & cancer.

[31]  V. Tonk,et al.  Interphase cytogenetic (in situ hybridization) analysis of astrocytomas using archival, formalin-fixed, paraffin-embedded tissue and nonfluorescent light microscopy. , 1997, American journal of clinical pathology.

[32]  G. Fuller,et al.  Diagnostic discrepancies and their clinical impact in a neuropathology referral practice , 1997, Cancer.

[33]  P. Burger,et al.  Stereotactic brain biopsies: specimen preparation and evaluation. , 1997, Archives of pathology & laboratory medicine.

[34]  Y. Yonekawa,et al.  Incidence and timing of p53 mutations during astrocytoma progression in patients with multiple biopsies. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[35]  D K Pearl,et al.  Improving diagnostic accuracy and interobserver concordance in the classification and grading of primary gliomas , 1997, Cancer.

[36]  A. Chitale,et al.  Squash Preparation and Frozen Section in Intraoperative Diagnosis of Central Nervous System Tumors , 1998, Acta Cytologica.

[37]  R. McLendon,et al.  Russell and Rubinstein's pathology of tumors of the nervous system , 1998 .

[38]  S. Coons,et al.  Mitosis identification in diffuse gliomas , 1998, Cancer.

[39]  P. Burger,et al.  Diagnostic synergy in radiology and surgical neuropathology: radiographic findings of specific pathologic entities. , 1998, Archives of pathology & laboratory medicine.

[40]  D. Louis,et al.  Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. , 1998, Journal of the National Cancer Institute.

[41]  P. Burger,et al.  Diagnostic synergy in radiology and surgical neuropathology: neuroimaging techniques and general interpretive guidelines. , 1998, Archives of pathology & laboratory medicine.

[42]  M. J. van den Bent,et al.  Genetic aberrations in oligodendroglial tumours: an analysis using comparative genomic hybridization (CGH) , 1999, The Journal of pathology.

[43]  Y. Yonekawa,et al.  Genetic profile of the giant cell glioblastoma. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[44]  B. Scheithauer,et al.  Cellular proliferation in pilocytic and diffuse astrocytomas. , 1999, Journal of neuropathology and experimental neurology.

[45]  A. von Deimling,et al.  Identification of subgroups of high-grade oligodendroglial tumors by comparative genomic hybridization. , 1999, Journal of neuropathology and experimental neurology.

[46]  B. Scheithauer,et al.  Localization of common deletion regions on 1p and 19q in human gliomas and their association with histological subtype , 1999, Oncogene.

[47]  A. Poustka,et al.  Comprehensive Allelotype and Genetic Analysis of 466 Human Nervous System Tumors , 2000, Journal of neuropathology and experimental neurology.

[48]  C. James,et al.  Diversity and frequency of epidermal growth factor receptor mutations in human glioblastomas. , 2000, Cancer research.

[49]  F. Abdul-Karim,et al.  Interobserver reproducibility among neuropathologists and surgical pathologists in fibrillary astrocytoma grading , 2000, Journal of the Neurological Sciences.

[50]  D. Louis,et al.  Long survival and therapeutic responses in patients with histologically disparate high-grade gliomas demonstrating chromosome 1p loss. , 2000, Journal of neurosurgery.

[51]  Webster K. Cavenee,et al.  Pathology and genetics of tumours of the nervous system. , 2000 .

[52]  L. Sobin,et al.  World Health Organization classification of tumors , 2000, Cancer.

[53]  P. Kleihues,et al.  Genetic profile of gliosarcomas. , 2000, The American journal of pathology.

[54]  B. Scheithauer,et al.  Alterations of chromosome arms 1p and 19q as predictors of survival in oligodendrogliomas, astrocytomas, and mixed oligoastrocytomas. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[55]  D. Rowitch,et al.  Oligodendrocyte lineage genes (OLIG) as molecular markers for human glial brain tumors , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[56]  G. Tortora,et al.  A novel approach in the treatment of cancer: targeting the epidermal growth factor receptor. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[57]  B. Scheithauer,et al.  Oligodendrogliomas: Reproducibility and Prognostic Value of Histologic Diagnosis and Grading , 2001, Journal of neuropathology and experimental neurology.

[58]  Robert B. Jenkins,et al.  Losses of Chromosomal Arms 1p and 19q in the Diagnosis of Oligodendroglioma. A Study of Paraffin-Embedded Sections , 2001, Modern Pathology.

[59]  A. Perry Oligodendroglial Neoplasms: Current Concepts, Misconceptions, and Folklore , 2001, Advances in anatomic pathology.

[60]  J. Hoffman New advances in brain tumor imaging , 2001, Current opinion in oncology.

[61]  B. Scheithauer,et al.  Genotype-Phenotype Correlation in Gemistocytic Astrocytomas , 2001, Neurosurgery.

[62]  Jean-Yves Delattre,et al.  OLIG2 as a specific marker of oligodendroglial tumour cells , 2001, The Lancet.

[63]  K. Aldape,et al.  Small Cell Architecture—A Histological Equivalent of EGFR Amplification in Glioblastoma Multiforme? , 2001, Journal of neuropathology and experimental neurology.

[64]  K. Hoang-Xuan,et al.  Molecular heterogeneity of oligodendrogliomas suggests alternative pathways in tumor progression , 2001, Neurology.

[65]  Andreas von Deimling,et al.  Impact of Genotype and Morphology on the Prognosis of Glioblastoma , 2002, Journal of neuropathology and experimental neurology.

[66]  P. Burger,et al.  What is an Oligodendroglioma? , 2002, Brain pathology.

[67]  D. Rowitch,et al.  An ‘oligarchy’ rules neural development , 2002, Trends in Neurosciences.

[68]  D. Brat,et al.  Infiltrative Astrocytomas With Granular Cell Features (Granular Cell Astrocytomas): A Study of Histopathologic Features, Grading, and Outcome , 2002, The American journal of surgical pathology.

[69]  P. Wesseling,et al.  Chromosomal imbalances in primary oligodendroglial tumors and their recurrences: clues about malignant progression detected using comparative genomic hybridization. , 2002, Journal of neurosurgery.

[70]  A. Twijnstra,et al.  Gain of chromosome 7, as detected by in situ hybridization, strongly correlates with shorter survival in astrocytoma grade 2 , 2002, Genes, chromosomes & cancer.

[71]  G. Reifenberger,et al.  Expression of oligodendrocyte lineage genes in oligodendroglial and astrocytic gliomas , 2004, Acta Neuropathologica.

[72]  D. Brat,et al.  Ancillary FISH analysis for 1p and 19q status: preliminary observations in 287 gliomas and oligodendroglioma mimics. , 2003, Frontiers in bioscience : a journal and virtual library.

[73]  Susan M. Chang,et al.  Grade II astrocytomas are subgrouped by chromosome aberrations. , 2003, Cancer genetics and cytogenetics.

[74]  T. Golub,et al.  Gene expression-based classification of malignant gliomas correlates better with survival than histological classification. , 2003, Cancer research.

[75]  M. Rosenblum Surgical Pathology of the Nervous System and Its Coverings, 4th ed. , 2003 .

[76]  D. Figarella-Branger,et al.  Shared oligodendrocyte lineage gene expression in gliomas and oligodendrocyte progenitor cells. , 2003, Journal of neurosurgery.

[77]  Erwin G. Van Meir,et al.  Alterations in molecular pathways of diffusely infiltrating glial neoplasms: application to tumor classification and anti-tumor therapy (Review). , 2003, International journal of oncology.

[78]  B. Scheithauer,et al.  Phase II trial of procarbazine, lomustine, and vincristine as initial therapy for patients with low-grade oligodendroglioma or oligoastrocytoma: efficacy and associations with chromosomal abnormalities. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[79]  Daniel J Brat,et al.  Genetic Markers in Glioblastoma: Prognostic Significance and Future Therapeutic Implications: On: Impact of Genotype Morphology on the Prognosis of Glioblastoma. Schmidt MC Antweiler S, Urban N, et al. J Neuropathol Exp Neurol 2002;61:321–328. , 2003, Advances in anatomic pathology.

[80]  B. Scheithauer,et al.  Clinical Utility of Fluorescence In Situ Hybridization (FISH) in Morphologically Ambiguous Gliomas with Hybrid Oligodendroglial/Astrocytic Features , 2003, Journal of neuropathology and experimental neurology.

[81]  Y. Sawamura,et al.  Expression of the Oligodendroglial Lineage‐Associated Markers Olig1 and Olig2 in Different Types of Human Gliomas , 2003, Journal of neuropathology and experimental neurology.

[82]  Caterina Giannini,et al.  Immunohistochemical Detection of EGFRvIII in High Malignancy Grade Astrocytomas and Evaluation of Prognostic Significance , 2004, Journal of neuropathology and experimental neurology.

[83]  L. J. Rubinstein,et al.  Immunohistochemical characterization of oligodendrogliomas: an analysis of multiple markers , 2004, Acta Neuropathologica.

[84]  C. Hartmann,et al.  Pathology and molecular genetics of oligodendroglial tumors , 2004, Journal of Molecular Medicine.

[85]  R. Vidal,et al.  Immunolocalization of the Oligodendrocyte Transcription Factor 1 (Olig1) in Brain Tumors , 2004, Journal of neuropathology and experimental neurology.

[86]  G. Reifenberger,et al.  Pathology and molecular genetics of astrocytic gliomas , 2004, Journal of Molecular Medicine.

[87]  H. Budka,et al.  Glial fibrillary acidic protein (GFAP) in oligodendroglial tumors: Gliofibrillary oligodendroglioma and transitional oligoastrocytoma as subtypes of oligodendroglioma , 2004, Acta Neuropathologica.

[88]  L. Nakopoulou,et al.  An immunocytochemical comparison of glial fibrillary acidic protein, S-100p and vimentin in human glial tumors , 1990, Journal of Neuro-Oncology.

[89]  P. Gass,et al.  Expression of oligodendroglia and Schwann cell markers in human nervous system tumors , 1992, Acta Neuropathologica.

[90]  Allan H Friedman,et al.  Phase II trial of gefitinib in recurrent glioblastoma. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[91]  D. Brat,et al.  Analysis of 1p, 19q, 9p, and 10q as prognostic markers for high-grade astrocytomas using fluorescence in situ hybridization on tissue microarrays from Radiation Therapy Oncology Group trials. , 2004, Neuro-oncology.

[92]  D. Brat,et al.  Delivery systems and molecular targets of mechanism-based therapies for GBM , 2004, Expert review of neurotherapeutics.

[93]  K. Aldape,et al.  Small cell astrocytoma: An aggressive variant that is clinicopathologically and genetically distinct from anaplastic oligodendroglioma , 2004, Cancer.

[94]  A. Korshunov,et al.  Molecular Stratification of Diagnostically Challenging High-Grade Gliomas Composed of Small Cells , 2004, Clinical Cancer Research.

[95]  Catherine L Nutt,et al.  The Oligodendroglial Lineage Marker OLIG2 Is Universally Expressed in Diffuse Gliomas , 2004, Journal of neuropathology and experimental neurology.

[96]  P. Wesseling,et al.  Molecular pathogenesis of oligodendroglial tumors , 2004, Journal of Neuro-Oncology.

[97]  K. Hoang-Xuan,et al.  Temozolomide as initial treatment for adults with low-grade oligodendrogliomas or oligoastrocytomas and correlation with chromosome 1p deletions. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[98]  B. Scheithauer,et al.  Supratentorial gliomas: a comparative study by grade and histologic type , 1997, Journal of Neuro-Oncology.

[99]  B. Feuerstein,et al.  Chromosomal imbalances detected by array comparative genomic hybridization in human oligodendrogliomas and mixed oligoastrocytomas , 2005, Genes, chromosomes & cancer.

[100]  K. Hoang-Xuan,et al.  Olig2 expression, GFAP, p53 and 1p loss analysis contribute to glioma subclassification , 2005, Neuropathology and applied neurobiology.

[101]  David J. Yang,et al.  Prognostic Effect of Epidermal Growth Factor Receptor and EGFRvIII in Glioblastoma Multiforme Patients , 2005, Clinical Cancer Research.

[102]  Rebecca A Betensky,et al.  YKL-40 Is a Differential Diagnostic Marker for Histologic Subtypes of High-Grade Gliomas , 2005, Clinical Cancer Research.

[103]  B. Scheithauer,et al.  Tumors of the Central Nervous System , 2007 .